ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

NIH Authorization Set For Another Try; Women’s Cancers Are Targeted

July 10, 1992

Funding Opportunities

November 15, 2002

Bast Named VP For Translational Research And Co-PI Of Core Grant At M. D. Anderson.

March 24, 2000

Stand Up To Cancer Says $80 Million in Pledges Raised

September 17, 2010

Dole to Press HCFA On Community DRG Exemptions, Calls For Meeting TO Assess Problems

March 16, 1984

Cyramza Combination Approved In Advanced Gastric Cancer

November 28, 2014